|
|
|
|
Approved Products_2004.xls
Number A pproval Date Trade Name Generic/ Chemical name Indication Company 1 Oct- 82 Humulin Human Insulin Type I Diabetes Lilly / Genentech 2 Oct- 85 Protro pin Human Growth Hormone Hypoptuitary dwarfism Genentech 3 Jun- 86 Intron A Interferon Al pha 2B Hairy Cell Leukemia Schering Plough / Biogen 4 Jun- 86 OKT- 3 Anti CD3 Mab Acute Trans plant Rejection JNJ / OrthoBiotech 5 Jun- 86...
author: Reijer
|
|
|
Approved Products_2004.xls page 1
author: Reijer
|
|
|
Database P
P - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
|
|
|
http://www.axcan.com/pdf/rap00_fr.pdf page 12
duplicates:
http://www.axcan.com/fr-fr/pdf/rap00_fr.pdf
http://www.axcan.com/fr-ca/pdf/rap00_fr.pdf
|
|
|
http://www.axcan.com/pdf/rap00_fr.pdf
Canada Nouveau marche ° PHOTOFRIN ° URSO Etats- Unis Nouvelles indications ° PHOTOFRIN ° URSO Nouveau marche ° PHOTOFRIN ° HELICIDE E rope Axcan connait une forte croissance sur trois fronts Augmentation du taux de penetration des marches actuels ° MODULON ° SALOFALK ° PHOTOFRIN Nouveau marche ° HELICIDE...
|
|
|
AXP-03-041 (corpo_fr) v4 page 26
author: poste 8
duplicates:
http://www.axcan.com/fr-fr/pdf/ResearchAndDevelopment_fr.pdf
http://www.axcan.com/fr-ca/pdf/rap03_fr.pdf
http://www.axcan.com/fr-ca/pdf/ResearchAndDevelopment_fr.pdf
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
4, ACETAMINOPHEN PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN PHENAZINE, PHENDIMETRAZINE TARTRATE PHENAZINE-35, PHENDIMETRAZINE TARTRATE PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE PHENERGAN W/ CODEINE, CODEINE...
|
|
|
EFFICACY SUPPLEMENTS APPROVED IN CALENDAR YEAR 2003
FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - - EFFICACY SUPPLEMENTS APPROVED IN CALENDAR YEAR 2003 (SE1 -SE7)* and EFFICACY SUPPLEMENTS APPROVED IN CALENDAR YEAR 2003 (SE8)* - GENERIC NAME APPLICANT NDA NUMBER SUPP TYPE SUPP NUMBER RECEIPT DATE APPROVAL DATE PRIORITY REVIEW TOTAL APPROVAL TIME (MONTHS) INDICATION/DESCRIPTION FLUOXETINE...
|
|
|
ASCO/FDA Lung Cancer Endpoints Workshop: Final Summary
Table 1 Drugs Specifically Approved for NSCLC - US EU JPN Docetaxel 1999 (1) /2002 (2) 1995 (1) /2002 (3) 1997 Gemcitabine 1998 1995 1995 Paclitaxel 1998 1998 1999 Vinorelbine 1994 1989 1999 Cisplatin - 1996 1984 Porfimer sodium 1998 (4) - 1995 (5) Gefitinib 2003 - 2002 (6) Amrubicin - - 2002 Carboplatin - - 2000 Irinotecan - - 1994 Nedaplatin - - 1995 (1) Second-line; (2)...
|
|
|
ASCO/FDA Lung Cancer Endpoints Workshop 4/15/03
Table 1 Drugs Specifically Approved for NSCLC US EU JPN Docetaxel 1999(1)/2002(2) 1995(1)/2002(3) 1997 Gemcitabine 1998 1995 1995 Paclitaxel 1998 1998 1999 Vinorelbine 1994 1989 1999 Cisplatin 1996 1984 Porfimer sodium 1998(4) 1995(5) Gefitinib 2003 2002(6) Amrubicin 2002 Carboplatin 2000 Irinotecan 1994 Nedaplatin 1995 (1)Second-line; (2)First-line; (3)First-line,...
|
|
|
ELIGIBILITY FORM (for the 1st 3 courses)
ELIGIBILITY FORM Photodynamic Therapy Porfimer Sodium (Photofrin ) (This form should be completed before the first dose is dispensed) 1. PATIENT SURNAME ______________________________ 2. GIVEN NAME____________________________ 3. DATE OF BIRTH __ __ __ __ __ __ Day Month Year 4. HEALTH ...
author: Provincial Office, OCTRF
|
|
|
ELIGIBILITY FORM (for the 1st 3 courses) page 1
ELIGIBILITY FORM Photodynamic Therapy Porfimer Sodium (Photofrin ) (This form should be completed before the first dose is dispensed) 1. PATIENT SURNAME ______________________________ 2. GIVEN NAME____________________________ 3. DATE OF BIRTH __ __ __ __ __ __ Day Month Year 4. HEALTH ...
author: Provincial Office, OCTRF
|
|
|
Dana-Farber Cancer Institute provides cancer information on all cancer types: Clinical Trials
Home : Cancer Information : National Clinical Trials Cancer Information by Disease What is Cancer? National Clinical Trials Cancer Prevention Screening & Detection Resources on the Web Dictionary of Medical ...
|
|
|
Dana-Farber Cancer Institute provides cancer information on all cancer types: Clinical Trials
Home : Cancer Information : National Clinical Trials Cancer Information by Disease What is Cancer? National Clinical Trials Cancer Prevention Screening & Detection Resources on the Web Dictionary of Medical ...
|
|
|
Cancer Care Ontario Formulary
Information for patients, health professionals and public on cancer prevention, screening, treatment (radiation, chemotherapy, surgery), supportive care, research, education, and standards and guidelines ...
|
|
|
01-058 PhRMA NewMedCanc 3/21.cc page 14
author: RL
|
|
|
Prescription and OTC Drug Product List 11/2000
Prescription and Over-the-Counter Drug Product List - 20th Edition Cumulative Supplement Number 11: November 2000 [ Prescription - OTC ] ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST - ADD - ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE AMOXICILLIN - ADD - TABLET; ORAL TABLET; ORAL - ADD - TRIZIVIR AMOXICILLIN - ADD - + GLAXO WELLCOME EQ 300MG BASE;150MG;300MG N21205 001 - ADD -...
|
|
|
FDA Drug Approvals List- January 1998
Drug Approvals for January 1998 Definitions and Notes January 1998 Original New Drug Applications Original Application #: 050731 Approval Date: 30-JAN-98 Trade Name: DAUNORUBICIN HCL Chemical Type: 3 Therapeutic Potential: S Dosage Form: INJECTABLE Applicant: BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC Active Ingredient(s): DAUNORUBICIN HYDROCHLORIDE OTC/RX Status: RX...
|
|
|
5 Year Index
SPECIAL REVIEW TECHNOLOGY UPDATE 5 Cyproterone acetate 1090 Flutamide 1090 Goserelin 1090 Leuprolide acetate 1091 Nilutamide 1091 OTHER CHEMOTHERAPEUTICS 1091 Alitretinoin 1091 Anthracyclines 1092 Daunorubicin 1092 Epirubicin 1092 Liposomal daunorubicin 1092 Liposomal doxorubicin 1092 Mitoxantrone 1094 Valrubicin 1094 Busulfan 1094 Carmustine Wafer 1094 Etoposide Phosphate 1095...
|
|
|
FDA Drug Approvals List July 2000
- Drug Approvals for July 2000 Definitions and Notes Original New Drug Applications Original Application #: 050779 Approval Date: 27-JUL-00 Trade Name: CEFAZOLIN AND DEXTROSE Chemical Type: 5 Therapeutic Potential: S Dosage Form: INJECTABLE Applicant: B BRAUN MEDICAL INC Active Ingredient(s): CEFAZOLIN SODIUM OTC/RX Status: RX Indication(s): For the treatment of respiratory tract...
|
|
|
http://www.cancercare.on.ca/formulary/pdfdrugs/PORFIMER.pdf
Porfimer CCO Formulary Revised Feb 2000 A DRUG NAME: PORFIMER SYNONYM( S): Porfimer sodium, Dihematoporphyrin ether, DHE COMMON TRADE NAME( S): Photofrin® (Ligand) B MECHANISM OF ACTION AND PHARMACOKINETICS Porfimer is a complex mixture of porphyrins that, when injected, is selectively retained ...
|
|
|
http://www.cancercare.on.ca/formulary/pdfdrugs/PORFIMER.pdf page 1
Porfimer CCO Formulary Revised Feb 2000 A DRUG NAME: PORFIMER SYNONYM( S): Porfimer sodium, Dihematoporphyrin ether, DHE COMMON TRADE NAME( S): Photofrin® (Ligand) B MECHANISM OF ACTION AND PHARMACOKINETICS Porfimer is a complex mixture of porphyrins that, when injected, is selectively retained ...
|
|
|
FDA Drug Approvals List- December 1998
Drug Approvals for December 1998 Definitions and Notes December 1998 Original New Drug Applications Original Application #: 020998 Approval Date: 31-DEC-98 Trade Name: CELEBREX Chemical Type: 1 Therapeutic Potential: P Dosage Form: CAPSULE Applicant: GD SEARLE AND CO Active Ingredient(s): CELECOXIB OTC/RX Status: RX Indication(s):For the signs and symptoms of osteoarthritis and...
|
|
|
DDPA December 1995
Drug and Device Approvals-December 1995 December 1995 - FDA Drug and Device Product Approvals ***ORIGINAL AND SUPPLEMENTAL NDAs*** FOR NEW DRUG PRODUCTS 20-628 INVIRASE ROCHE SAQUINAVIR MESYLATE 06-DEC-95 (CAPSULE) NUTLEY, NJ EQ 200MG BASE (1 P, AA*, E**, H***) 07110 (ANTIVIRAL) [TREATMENT OF ADVANCED HIV INFECTION IN SELECTED PATIENTS IN COMBINATION WITH NUCLEOSIDE ANALOGUES] 19-835...
|
|
|
*AXP-02-042-trimes FR page 4
author: Mario
duplicates:
http://www.axcan.com/fr-ca/pdf/Q2-2002_fr.pdf
http://www.axcan.com/pdf/Q2-2002_fr.pdf
|
